Dr. Reddy's Laboratories Limited (BOM: 500124)
India
· Delayed Price · Currency is INR | Market Cap | 1.08T |
| Revenue (ttm) | 299.87B |
| Net Income (ttm) | 53.33B |
| Shares Out | 833.09M |
| EPS (ttm) | 63.95 |
| PE Ratio | 20.36 |
| Forward PE | 17.84 |
| Dividend | 8.00 (0.61%) |
| Ex-Dividend Date | Jul 16, 2024 |
| Volume | 20,238 |
| Average Volume | 104,693 |
| Open | 1,306.90 |
| Previous Close | 1,309.85 |
| Day's Range | 1,294.00 - 1,306.95 |
| 52-Week Range | 1,120.01 - 1,420.20 |
| Beta | 0.36 |
| RSI | 43.31 |
| Earnings Date | Jan 23, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI se... [Read more]
Financial Performance
In 2023, Dr. Reddy's Laboratories's revenue was 279.16 billion, an increase of 13.54% compared to the previous year's 245.88 billion. Earnings were 55.68 billion, an increase of 23.56%.
Financial StatementsNews
Dr Reddy’s, DRF launch soil testing resource centre in Hyderabad to boost agriproductivity & sustainability
Hyderabad: Dr Reddy's Laboratories Limited (DRL), along with the Dr Reddy's Foundation (DRF), has set up a soil testing resource centre (STRC) spread .
Nifty 50 top losers today on January 16: Trent, Dr. Reddy’s Laboratories, Tata Consumer Products and more
Indian stock markets experienced another positive session on January 16, 2025, marking a third consecutive day of gains. The Nifty 50 Index continued its upward momentum, surpassing the 23,300 mark, w...
Pharma stocks: Dr. Reddy’s up 1.70%, Biocon down 2.17%, Lupin falls 2.18%
As of 10:58 AM, pharma stocks exhibited mixed performance. Here are the key highlights: Gainers: Dr. Reddy’s Laboratories: Leading the gains with a 1.70% rise, trading at ₹1,374.55. Cipla: Slight upti...
Dr Reddys shares rally today after Nuvama upgrades stock to ‘Buy’
Shares of Dr. Reddy’s Laboratories Limited surged by 2.88% to ₹1,390.50 in early trading today after Nuvama Research upgraded the stock to a ‘Buy’ from ‘Reduce,’ citing proactive measures by the compa...
Dr. Reddy’s Laboratories shares jump 3% on subsidiary sale announcement
Dr. Reddy’s Laboratories witnessed a 3% surge in its stock price following the announcement of selling its step-down subsidiary, Dr. Reddy’s Laboratories Louisiana LLC (DRLL). The deal, finalized on J...
Nuvama on Dr. Reddy’s share: Upgrade to Buy, expects 14.8% upside citing strategies to offset Revlimid expiry impact
Nuvama has upgraded its rating on Dr. Reddy’s Laboratories (DRL) to ‘Buy’ with a target price of ₹1,553/share, reflecting a potential upside of 14.8% from the current market price (CMP) of ₹1,352.75. ...
Dr. Reddy’s Laboratories announces sale of Louisiana manufacturing facility and subsidiary
The sale aligns with Dr. Reddy’s strategic focus on optimizing its global operations. As stated by the company, the Shreveport facility has not been integral to its long-term product development pipel...
Pharma sector stocks performance: Ipca Labs gains 1.23%, Biocon up 0.84%, Sun Pharma and Torrent Pharma slip over 1%
Pharma sector stocks displayed a mixed trend as of 10:33 AM. Ipca Labs led the gainers with a 1.23% rise, followed by Biocon at 0.84% and Dr. Reddy’s at 0.65%. On the downside, Sun Pharma (-1.15%), Au...
Nifty 50 top losers today on January 1, 2025: Hindalco Industries, Dr. Reddy’s Laboratories, Adani Ports and more
Indian equity markets ended on a positive note on January 1, 2025, with the Nifty crossing the crucial 23,700 mark. The Sensex surged by 368.40 points, or 0.47 percent, closing at 78,507.41, while the...
Aurobindo Pharma (+1.58%), Mankind Pharma (+1.48%), Zydus Lifesciences (+0.91%) lead pharma stock gains
As of 10:00 AM, pharma stocks are trading mixed, with Aurobindo Pharma, Mankind Pharma, and Zydus Lifesciences emerging as top gainers. Meanwhile, Biocon (-0.72%), Ipca Labs (-0.40%), and Dr. Reddy’s ...
Nifty 50 top gainers today on December 27: Dr. Reddy’s Laboratories, IndusInd Bank, Mahindra & Mahindra and more
On December 27, Indian benchmark indices continued their positive momentum, ending with gains. The Sensex closed up by 226.59 points, or 0.29%, at 78,699.07, while the Nifty gained 63.20 points, or 0....
Healthcare Sector Stock Update: Sun Pharma up 1.05%, Cipla up 1.22%, Zydus Lifesciences up 2%
The healthcare sector displayed a varied performance in today’s trading session, with pharmaceutical giants leading gains while hospital operators experienced mixed trends. Gainers: Sun Pharmaceutical...
Nifty 50 top gainers this week: Dr. Reddy’s Laboratories and Cipla shine amid market turmoil
The Indian equity benchmarks, Nifty 50 and Sensex, experienced their sharpest decline in four months on Friday, December 20. The Sensex tumbled 1,176 points, closing at 78,042, while the Nifty 50 drop...
Nifty 50 top gainers today on December 20: Dr. Reddy’s Laboratories, JSW Steel, ICICI Bank and more
The Indian equity market concluded on a somber note today, December 20, with indices reflecting a widespread sell-off across sectors. The Nifty 50 index slipped below the crucial 23,600 mark, while th...
Top gainers on Nifty 50: Bajaj Finance up 1.33%, Titan surges 1.43%, Dr. Reddy adds 1.9% as index gains 0.30%
The Nifty 50 rose by 72 points (+0.30%) to ₹24,023.70 as of 9:40 AM, supported by gains across major constituents. Key stocks in the spotlight include Bajaj Finance, Titan, and Dr. Reddy’s Laboratorie...
Nifty 50 top gainers today on December 19: Dr. Reddy’s Laboratories, Cipla, Bharat Petroleum and more
Indian benchmark indices continued their downward trend on December 19, marking the fourth consecutive session of losses. At the close, the Sensex dropped by 964.15 points (1.20%) to 79,218.05, while ...
Dr. Reddy’s stock jumps as Nomura upgrades to ‘Buy’ with Rs 1,500 target
Dr. Reddy’s Laboratories saw its stock jump 1% in a weak market after Nomura upgraded it to a ‘Buy’ with a target price of ₹1,500. The brokerage highlighted the stock’s underperformance and its growth...
Nomura upgrades Dr. Reddy’s to ‘Buy’, target price at Rs 1,500
Nomura has upgraded Dr. Reddy’s Laboratories to a ‘Buy’ rating, with a target price of ₹1,500/share
Nifty 50 top gainers today on December 18: Trent, Dr. Reddy’s Laboratories, Cipla and more
On December 18, Indian benchmark indices faced a decline for the third consecutive session, with the Nifty closing below the crucial 24,200 mark. The BSE Sensex fell by 502.25 points, or 0.62%, settli...
Nifty 50 top gainers today on December 16: Dr. Reddy’s Laboratories, IndusInd Bank, HDFC Life Insurance and more
Indian equity indices closed trading on December 16 with a negative note. The Sensex dropped by 384.55 points, or 0.47%, settling at 81,748.57, while the Nifty ended lower by 100.05 points, or 0.40%, ...
Pharma stocks: Sun Pharma up 1.27%, Dr. Reddy’s rises 0.82%, Cipla gains 0.53%
The pharmaceutical sector saw broad-based gains in early trade on November 29, 2024, with Cipla and Sun Pharma leading the charge. Here’s a detailed look at the top pharma stocks as of 10:34 AM: Stock...
Dr Reddy launches world's 1st immuno-onco drug for nasopharyngeal cancer in India
Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare head a...
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India.
Dr. Reddy’s launches Toripalimab in India, a breakthrough immuno-oncology drug for nasopharyngeal carcinoma
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has launched Toripalimab in India, marking the country as the third globally to access this groundbreaking immuno-oncology drug aft...
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.